Pelargonidin-3-O-rutinosde chlorideCAS# 33978-17-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 33978-17-5 | SDF | Download SDF |
PubChem ID | 14841214 | Appearance | Powder |
Formula | C27H31O14Cl | M.Wt | 615.0 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R,3R,4R,5R,6S)-2-[[(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)chromenylium-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol;chloride | ||
SMILES | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C([O+]=C4C=C(C=C(C4=C3)O)O)C5=CC=C(C=C5)O)O)O)O)O)O)O.[Cl-] | ||
Standard InChIKey | FTBRTFUYRINBHS-DMONZEQBSA-N | ||
Standard InChI | InChI=1S/C27H30O14.ClH/c1-10-19(31)21(33)23(35)26(38-10)37-9-18-20(32)22(34)24(36)27(41-18)40-17-8-14-15(30)6-13(29)7-16(14)39-25(17)11-2-4-12(28)5-3-11;/h2-8,10,18-24,26-27,31-36H,9H2,1H3,(H2-,28,29,30);1H/t10-,18+,19-,20+,21+,22-,23+,24+,26+,27+;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Pelargonidin 3-Rutinoside exhibits antioxidant and anti-inflammatory properties. |
Targets | Immunology & Inflammation related |
Pelargonidin-3-O-rutinosde chloride Dilution Calculator
Pelargonidin-3-O-rutinosde chloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.626 mL | 8.1301 mL | 16.2602 mL | 32.5203 mL | 40.6504 mL |
5 mM | 0.3252 mL | 1.626 mL | 3.252 mL | 6.5041 mL | 8.1301 mL |
10 mM | 0.1626 mL | 0.813 mL | 1.626 mL | 3.252 mL | 4.065 mL |
50 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.6504 mL | 0.813 mL |
100 mM | 0.0163 mL | 0.0813 mL | 0.1626 mL | 0.3252 mL | 0.4065 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Triacetonamine hydrochloride
Catalog No.:BCN5264
CAS No.:33973-59-0
- Z-Leu-Osu
Catalog No.:BCC2592
CAS No.:3397-35-1
- H-D-Phe(4-Cl)-OMe.HCl
Catalog No.:BCC3174
CAS No.:33965-47-8
- Thalrugosidine
Catalog No.:BCN7785
CAS No.:33954-34-6
- Anamorelin Fumarate
Catalog No.:BCC1363
CAS No.:339539-92-3
- UBP1112
Catalog No.:BCC7033
CAS No.:339526-74-8
- Boc-Ile-Osu
Catalog No.:BCC2604
CAS No.:3392-08-3
- Boc-Gly-OSu
Catalog No.:BCC3397
CAS No.:3392-07-2
- Boc-Ala-OSu
Catalog No.:BCC3048
CAS No.:3392-05-0
- 2,3,4'-Trihydroxy-3',5'-dimethoxypropiophenone
Catalog No.:BCN1455
CAS No.:33900-74-2
- Vandetanib trifluoroacetate
Catalog No.:BCC2029
CAS No.:338992-53-3
- Mdivi 1
Catalog No.:BCC2402
CAS No.:338967-87-6
- Clivorine
Catalog No.:BCN2067
CAS No.:33979-15-6
- 7-Oxodehydroabietinol
Catalog No.:BCN5265
CAS No.:33980-71-1
- Z-Ala-OSu
Catalog No.:BCC3057
CAS No.:3401-36-3
- Vinorine
Catalog No.:BCN4649
CAS No.:34020-07-0
- 1-BCP
Catalog No.:BCC6909
CAS No.:34023-62-6
- H-D-Phe-OtBu.HCl
Catalog No.:BCC3014
CAS No.:3403-25-6
- Auranofin
Catalog No.:BCC7952
CAS No.:34031-32-8
- SMIFH2
Catalog No.:BCC6162
CAS No.:340316-62-3
- Diclofensine hydrochloride
Catalog No.:BCC5541
CAS No.:34041-84-4
- 1,3-Bis(4,5-dihydro-2-oxazolyl)benzene
Catalog No.:BCC8417
CAS No.:34052-90-9
- 2-2'-(Hydroxytetracosanoylamino)-octadecane-1,3,4-triol tetraacetate
Catalog No.:BCN1454
CAS No.:340702-68-3
- Z-Pro-NH2
Catalog No.:BCC2753
CAS No.:34079-31-7
Genomic analysis of Isometamidium Chloride resistance in Trypanosoma congolense.[Pubmed:29032180]
Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):350-361.
Isometamidium Chloride (ISM) is one of the principal drugs used to counteract Trypanosoma congolense infection in livestock, both as a prophylactic as well as a curative treatment. However, numerous cases of ISM resistance have been reported in different African regions, representing a significant constraint in the battle against Animal African Trypanosomiasis. In order to identify genetic signatures associated with ISM resistance in T. congolense, the sensitive strain MSOROM7 was selected for induction of ISM resistance in a murine host. Administered ISM concentrations in immune-suppressed mice were gradually increased from 0.001 mg/kg to 1 mg/kg, the maximal dose used in livestock. As a result, three independent MSOROM7 lines acquired full resistance to this concentration after five months of induction, and retained this full resistant phenotype following a six months period without drug pressure. In contrast, parasites did not acquire ISM resistance in immune-competent animals, even after more than two years under ISM pressure, suggesting that the development of full ISM resistance is strongly enhanced when the host immune response is compromised. Genomic analyses comparing the ISM resistant lines with the parental sensitive line identified shifts in read depth at heterozygous loci in genes coding for different transporters and transmembrane products, and several of these shifts were also found within natural ISM resistant isolates. These findings suggested that the transport and accumulation of ISM inside the resistant parasites may be modified, which was confirmed by flow cytometry and ex vivo ISM uptake assays that showed a decrease in the accumulation of ISM in the resistant parasites.
Effects of Extended Storage of Chlorhexidine Gluconate and Benzalkonium Chloride Solutions on the Viability of Burkholderia cenocepacia.[Pubmed:29032643]
J Microbiol Biotechnol. 2017 Dec 28;27(12):2211-2220.
Chlorhexidine gluconate (CHX) and benzalkonium chloride (BZK) formulations are frequently used as antiseptics in healthcare and consumer products. Burkholderia cepacia complex (BCC) contamination of pharmaceutical products could be due to the use of contaminated water in the manufacturing process, over-diluted antiseptic solutions in the product, and the use of outdated products, which in turn reduces the antimicrobial activity of CHX and BZK. To establish a "safe use" period following opening containers of CHX and BZK, we measured the antimicrobial effects of CHX (2-10 mug/ml) and BZK (10-50 mug/ml) at sublethal concentrations on six strains of Burkholderia cenocepacia using chemical and microbiological assays. CHX (2, 4, and 10 mug/ml) and BZK (10, 20, and 50 mug/ml) stored for 42 days at 23 degrees C showed almost the same concentration and toxicity compared with freshly prepared CHX and BZK on B. cenocepacia strains. When 5 mug/ml CHX and 20 mug/ml BZK were spiked to six B. cenocepacia strains with different inoculum sizes (10(0) -10(5) CFU/ml), their toxic effects were not changed for 28 days. B. cenocepacia strains in diluted CHX and BZK were detectable at concentrations up to 10(2) CFU/ml after incubation for 28 days at 23 degrees C. Although abiotic and biotic changes in the toxicity of both antiseptics were not observed, our results indicate that B. cenocepacia strains could remain viable in CHX and BZK for 28 days, which in turn, indicates the importance of control measures to monitor BCC contamination in pharmaceutical products.
Chloride-Tolerant Gold(I)-Catalyzed Regioselective Hydrochlorination of Alkynes.[Pubmed:29034119]
ACS Catal. 2017 Oct 6;7(10):6798-6801.
We have developed a highly regioselective homogeneous gold(I)-catalyzed anti-hydrochlorination of unactivated alkynes at room temperature. We have overcome the incompatibility between conventional cationic gold catalysts and chloride by using a hydrogen-bonding activation of the Au-Cl bond. This approach is scalable, exhibits excellent functional group tolerance, and can be conducted in open air.
Heterogeneous electro-Fenton catalyst for 1-butylpyridinium chloride degradation.[Pubmed:29034428]
Environ Sci Pollut Res Int. 2019 Feb;26(4):3145-3156.
The application of the electro-Fenton process for organic compound mineralisation has been widely reported over the past years. However, operational problems related to the use of soluble iron salt as a homogeneous catalyst involve the development of novel catalysts that are able to operate in a wide pH range. For this purpose, polyvinyl alcohol-alginate beads, containing goethite as iron, were synthesised and evaluated as heterogeneous electro-Fenton catalyst for 1-butylpyridinium chloride mineralisation. The influence of catalyst dosage and pH solution on ionic liquid degradation was analysed, achieving almost total oxidation after 60 min under optimal conditions (2 g/L catalyst concentration and pH 3). The results showed good catalyst stability and reusability, although its effectiveness decreases slightly after three successive cycles. Furthermore, a plausible mineralisation pathway was proposed based on the oxidation byproducts determined by chromatographic techniques. Finally, the Microtox(R) test revealed notable detoxification after treatment which demonstrates high catalyst ability for pyridinium-based ionic liquid degradation by the electro-Fenton process.
Effect of choline chloride premedication on xylazine-induced hypoxaemia in sheep.[Pubmed:29033246]
Vet Anaesth Analg. 2017 Sep;44(5):1149-1155.
OBJECTIVE: To determine the anti-inflammatory efficacy of choline in vivo and in vitro and to investigate the anti-inflammatory mechanisms of choline. STUDY DESIGN: Randomized, controlled studies. ANIMALS: In vivo trials used 16 Romney sheep. In vitro experiments utilized RAW 264.7 mouse macrophage cells. METHODS: Hypoxaemia induced in 16 sheep by intravenous (IV) injection of 50 mug kg(-1) xylazine, an alpha-2 agonist, was measured in sheep at 0, 1 and 4 minutes using arterial blood gas analysis with and without 50 mg kg(-1) IV choline chloride premedication. Cell culture studies used enzyme-linked immunosorbent assay to measure the release of tumour necrosis factor (TNF-alpha) from lipopolysaccharide (LPS) stimulated macrophages with and without choline chloride premedication. TNF-alpha release was compared to thalidomide suppressed and untreated cells. RESULTS: Choline premedication in sheep mitigated a reduction in arterial partial pressure of oxygen (PaO2) but did not prevent development of clinically significant hypoxaemia. Decrease in mean PaO2 of choline treated sheep was 6.36 kPa (47.7 mmHg) compared to 9.81 kPa (73.6 mmHg) in control sheep. In vitro studies demonstrate that choline administered concurrent with LPS activation did not significantly suppress TNF-alpha expression but that treatment of cells with choline 10 minutes prior to LPS activation did significantly suppress TNF-alpha expression. Choline pretreated cells expressed 23.99 +/- 4.52 ng mg(-1) TNF-alpha while LPS only control cells expressed 33.83 +/- 3.20 ng mg(-1). CONCLUSIONS: Choline is able to prevent macrophage activation in vitro when administered prior to LPS activation and may reduce hypoxaemia in sheep developing pulmonary oedema after xylazine administration. This effect requires premedication with choline. CLINICAL RELEVANCE: Pharmacological manipulation of autonomic inflammatory responses holds promise for the treatment of inflammation. However, the complex cellular mechanisms involved in this reflex means that an adequate therapy should approach multiple pathways and mechanisms of the inflammatory response.